High-Affinity Interaction of Sartans with H⁺/Peptide TransportersKNÜTTER, Ilka; KOTTRA, Gabor; FISCHER, Wiebke et al.Drug metabolism and disposition. 2009, Vol 37, Num 1, pp 143-149, issn 0090-9556, 7 p.Article

Association IEC-sartans: que faut-il en penser ? : Hypertension arterielleLa Revue du praticien (Paris). 2010, Vol 60, Num 5, issn 0035-2640, p. 632Article

Sartans: excès de cancers ? = Angiotensin-receptor blocking agent (sartans) and risk of cancersLa Revue Prescrire. 2010, Vol 30, Num 323, issn 0247-7750, p. 672Article

Sartans et risque de cancerBABAI, Samy; BROCVIELLE, Hélène; LEBELLER, Christine et al.Médecine (Montrouge). 2010, Vol 6, Num 9, issn 1777-2044, p. 405Article

IEC, sartans ou les deux ?AMBROSI, Pierre.MT. Médecine thérapeutique. 2010, Vol 16, Num 4, pp 374-378, issn 1264-6520, 5 p.Article

IEC et sartans : méta-analyse 2007 : Deuxième partie: traitement de l'insuffisance cardiaqueGUEYFFIER, Francois; NOËL-BARON, Florence.Médecine (Montrouge). 2007, Vol 3, Num 8, pp 346-351, issn 1777-2044, 6 p.Article

Angioödeme durch ACE-Hemmer und AT1-Rezeptor blocker = Angioedema due to ACE inhibitors and AT₁ receptor antagonistsHELLEBRAND, M.-C; KOIDA, G; HOFFMANN, T. K et al.Hautarzt. 2006, Vol 57, Num 9, pp 808-810, issn 0017-8470, 3 p.Article

Prevention of Vascular Injury by Combination of an AT₁ Receptor Blocker, Olmesartan, With Various Calcium AntagonistsINABA, Shinji; IWAI, Masaru; TOMONO, Yumiko et al.American journal of hypertension. 2009, Vol 22, Num 2, pp 145-150, issn 0895-7061, 6 p.Article

Peut-on (quand ?) associer IEC et sartans ?: Canadian Medical Association Journal, 5 avril 2011: prudence chez la personneLE NOC, Yves.Médecine (Montrouge). 2011, Vol 7, Num 6, pp 255-256, issn 1777-2044, 2 p.Article

Olmesartan Attenuates Cardiac Remodeling Through DLL4/Notch1 Pathway Activation in Pressure Overload MiceJIEYUN YOU; JIAN WU; GUOLIANG JIANG et al.Journal of cardiovascular pharmacology. 2013, Vol 61, Num 2, pp 142-151, issn 0160-2446, 10 p.Article

Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary EvidenceVOLPE, Massimo; TOCCI, Giuliano.Drugs & aging. 2013, Vol 30, Num 12, pp 987-998, issn 1170-229X, 12 p.Article

The Use of Modeling and Simulation to Guide Clinical Development of Olmesartan Medoxomil in Pediatric SubjectsSALAZAR, D. E; SONG, S. H; SHI, J et al.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 2, pp 250-256, issn 0009-9236, 7 p.Article

Predictors of Blood Pressure Response to the Angiotensin Receptor Blocker Candesartan in Essential HypertensionCANZANELLO, Vincent J; BARANCO-PRYOR, Evelyn; RAHBARI-OSKOUI, Frederic et al.American journal of hypertension. 2008, Vol 21, Num 1, pp 61-66, issn 0895-7061, 6 p.Article

Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-γWALCHER, Daniel; HESS, Katharina; MARX, Nikolaus et al.Hypertension (Dallas, Tex. 1979). 2008, Vol 51, Num 2, pp 259-266, issn 0194-911X, 8 p.Article

Iec ou sartan + diurétique + ains : Gare ! = Angiotensin converting enzyme inhibitor or sartan + diuretic + NSAIs : warning !La Revue Prescrire. 2007, Vol 27, Num 279, pp 22-22, issn 0247-7750, 1 p.Article

Antiarythmiques à l'étage atrial : perspectives = Atrial antiarrhythmics : PerspectivesDAVY, J.-M; RACZKA, F; CUNG, T.-T et al.Archives des maladies du coeur et des vaisseaux. 2006, Vol 99, pp 23-29, issn 0003-9683, 7 p., NS5Conference Paper

Olmésartan: entéropathiesLa Revue Prescrire. 2013, Vol 33, Num 362, issn 0247-7750, p. 913Article

Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartanSHANQUN JIANG; HSU, Yi-Hsiang; VENNERS, Scott A et al.Journal of hypertension. 2011, Vol 29, Num 5, pp 890-895, issn 0263-6352, 6 p.Article

Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imagingMIZUGUCHI, Yukio; OISHI, Yoshifumi; MIYOSHI, Hirokazu et al.Journal of hypertension. 2009, Vol 27, Num 9, pp 1892-1899, issn 0263-6352, 8 p.Article

Cardioprotective Mechanism of Telmisartan via PPAR-γ-eNOS Pathway in Dahl Salt-Sensitive Hypertensive RatsKOBAYASHI, Naohiko; OHNO, Tomoyuki; MATSUOKA, Hiroaki et al.American journal of hypertension. 2008, Vol 21, Num 5, pp 576-581, issn 0895-7061, 6 p.Article

Uricosuric Action of Losartan via the Inhibition of Urate Transporter 1 (URAT1) in Hypertensive PatientsHAMADA, Toshihiro; ICHIDA, Kimiyoshi; SHIGAMASA, Chiaki et al.American journal of hypertension. 2008, Vol 21, Num 10, pp 1157-1162, issn 0895-7061, 6 p.Article

Olmesartan: sprue-like enteropathyPrescrire international (Paris). 2014, Vol 23, Num 148, issn 1167-7422, p. 102Article

Effect of Telmisartan on Forearm Postischemic Hyperemia and Serum Asymmetric Dimethylarginine LevelsTOMIYAMA, Hirofumi; YAMADA, Jiko; KOJI, Yutaka et al.American journal of hypertension. 2007, Vol 20, Num 12, pp 1305-1313, issn 0895-7061, 9 p.Article

Triple Phase Budesonide Capsules for the Treatment of Olmesartan-Induced EnteropathyHARTRANFT, Megan E; REGAL, Randolph E.The Annals of pharmacotherapy. 2014, Vol 48, Num 9, pp 1234-1237, issn 1060-0280, 4 p.Article

Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertensionKURATA, M; OKURA, T; IRITA, J et al.Journal of human hypertension. 2011, Vol 25, Num 5, pp 334-339, issn 0950-9240, 6 p.Article